Evaluation of LAT1 Expression in Patients with Lung Cancer and Mediastinal Tumors: 18F-FBPA PET Study with Immunohistological Comparison

  • Tadashi Watabe
  • , Naoko Ose
  • , Sadahiro Naka
  • , Eriko Fukui
  • , Toru Kimura
  • , Takashi Kanou
  • , Soichiro Funaki
  • , Hidetaka Sasaki
  • , Takashi Kamiya
  • , Kenta Kurimoto
  • , Kayako Isohashi
  • , Mitsuaki Tatsumi
  • , Eku Shimosegawa
  • , Hiroki Kato
  • , Ryuichi Ohgaki
  • , Yoshikatsu Kanai
  • , Yasushi Shintani

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

Purpose of the Report L-type amino acid transporter-1 (LAT1) is a tumor-specific transporter expressed in various tumor types, with minimal expression in normal organs. We previously demonstrated 18F-fluoro-borono-phenylalanine (18F-FBPA) as a selective PET probe for LAT1 in a preclinical study. Herein, we evaluated LAT1 expression in preoperative patients with lung or mediastinal tumors using 18F-FBPA PET and immunofluorescence staining. Patients and Methods The study population included patients with histopathological diagnosis (n = 55): primary lung cancers (n = 21), lung metastases (n = 6), mediastinal tumors (n = 15), and benign lesion (n = 13). PET scanning was performed 1 hour after the injection of 18F-FBPA (232 ± 32 MBq). Immunofluorescence staining was performed on the resected tumor sections using LAT1 antibody. LAT1 staining was graded on a 4-grade scale and compared with the SUVmax on 18F-FBPA PET. Results A positive correlation was observed between the SUVmax of 18F-FBPA PET and LAT1 expression by immunofluorescence staining (r = 0.611, P < 0.001). The SUVmax of 18F-FBPA was 3.92 ± 1.46 in grade 3, 3.21 ± 1.82 in grade 2, 2.33 ± 0.93 in grade 1, and 1.50 ± 0.39 in grade 0 of LAT1 expression. Although 18F-FBPA PET showed variable uptake in lung cancers and mediastinal tumors, benign lesions showed significantly lower SUVmax than those in malignant lesions (P < 0.01). Conclusions Uptake on 18F-FBPA PET reflected the expression level of LAT1 in lung and mediastinal tumors. It was suggested that 18F-FBPA PET can be used for the precise characterization of the tumor in pretreatment evaluation.

Original languageEnglish
Pages (from-to)853-860
Number of pages8
JournalClinical nuclear medicine
Volume48
Issue number10
DOIs
Publication statusPublished - 01-10-2023
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Evaluation of LAT1 Expression in Patients with Lung Cancer and Mediastinal Tumors: 18F-FBPA PET Study with Immunohistological Comparison'. Together they form a unique fingerprint.

Cite this